Adalimumab (a fully human anti-tumour necrosis factor α monoclonal antibody) in the treatment of active rheumatoid arthritis: The initial results of five trials

Annals of the Rheumatic Diseases

Volumn 61, Issue SUPPL. 2, 2002, Pages

  Rau, R ^a  

^a Evangelisches Fachkrankenhaus Ratingen ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANALGESIC AGENT; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTHRITIS; BONE RADIOGRAPHY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; RANDOMIZED CONTROLLED TRIALS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036839225     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-11.
2. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328-46.
3. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
4. Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988;31:1041-5.
5. Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986;319:516-18.
6. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986;322:547-9.
7. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
8. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
9. Enbrel (Etanercept) [Package Insert]. Seattle, WA: Immunex Corporation, 2000.
10. Remicade (Infliximab) [Package Insert]. Malvern, PA: Centocor Inc, 1999.
11. Salfeld J, Kaymakçalan Z, Tracey D, Roberts A, Kamen R. Generation of fully human anti-TNF antibody D2E7. [Abstract]. Arthritis Rheum 1998;41 (suppl):S57.
12. Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7. Ann Rheum Dis 1999;58 (suppl):170-2.
13. Kempeni J. Update on D2E7: a fully human anti-tumour necrosis factor α monoclonal antibody. Ann Rheum Dis 2000;59 (suppl):144-5.
14. Barrera P, Joosten LA, den Broeder AA, et al. Effects of treatment with a fully human anti-tumour necrosis factor α monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF α in patients with rheumatoid arthritis. Ann Rheum Dis 2001;60:660-9.
15. Den Broeder AA, Joosten LA, Saxne T, et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: Effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 2002;61:311-18.
16. Barrera P, van Der Maas A, van Ede AE, et al. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis. Rheumatology (Oxford) 2002;41:430-9.
17. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
18. van Gestel AM, Prevoo ML, van't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 1996;39:34-40.
19. Breedveld FC, Allaart CF, Rau R, et al. The fully human anti-TNF antibody adalimumab (D2E7) in combination with methotrexate (MTX) in the treatment of active rheumatoid arthritis: results of a 2-year study. Ann Rheum Dis 2001;60 (suppl 1):OP 0062.
20. den Broeder A, van de Putte LBA, Rau R, Schattenkirchner M, van Riel PLCM, Sander O, et al. A single-dose, placebo-controlled study of the fully human anti-TNF antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol (in press).
21. Rau R, Herborn G, Sander O, van de Putte LBA, van Riel PLC, den Broeder A, et al. Long-term treatment with the fully human anti-TNF-antibody D2E7 slows radiographic disease progression in rheumatoid arthritis. [Abstract]. Arthritis Rheum 1999;42 (suppl):S400.
22. Schattenkirchner M, Krüger K, Sander O, Rau R, Kroot E-J, van Riel PLCM, et al. Efficacy and tolerability of weekly subcutaneous injections of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis-results of a phase I study. [Abstract]. Arthritis Rheum 1998;41 (suppl):S57.
23. van de Putte L BA, Rau R, Breedveld FC, et al. Efficacy of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis. [Abstract]. Arthritis Rheum 1999;42 (suppl):S400.
24. Keystone E, Weinblatt M, Furst D, et al. The ARMADA trial: a double-blind placebo controlled trial of the fully human anti.TNF monoclonal antibody, adalimumab (D2E7), in patients with active RA on methotrexate (MTX). [Abstract]. Arthritis Rheum 2001;44 (suppl):S213.
25. Rau R, Sander O, den Broeder A, et al. Long-term efficacy and tolerability of multiple I.V. doses of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis. [Abstract]. Arthritis Rheum 1998;41 (suppl):S55.